tbuckley/cabot-search huggingface dataset:
Information needs of men on androgen deprivation therapy.
Authors: T. Soeyonggo, P. R. Warde, N. Fleshner, N. Timilshina, S. Hussain, S. M. Alibhai
Journal: Journal of Clinical Oncology (2010)

e15093 Background: Androgen Deprivation Therapy (ADT) is commonly used in the treatment of prostate cancer. However, little is known about patients' information needs regarding ADT. This area is important as it may directly impact on patients' clinical care, adherence to therapy, and satisfaction with treatment. Methods: A cross-sectional survey was distributed to 83 patients who visited the prostate clinic at the Princess Margaret Hospital, Toronto, Ontario. Eligible men included those who spoke English and were on ADT adjuvant to radiation therapy or radical prostatectomy or for biochemical relapse. Three cohorts of men were recruited based on duration of ADT use: men who were on ADT for < 6 months (n=22), between 6 to 18 months (n=25), and 18 months to 4 years (n=36). For patients on adjuvant ADT, patients' quantitative perceptions of their own prognosis with and without ADT were obtained by eliciting survival probabilities at 5-, 10-, and 15-years. Patients' reported understanding of side effects with ADT was analyzed using thematic analyses. Patients on ADT for <6 months were asked about education by their physician at the time of ADT initiation. Analyses were primarily descriptive for the overall cohort and based on duration of ADT use. Results: Mean patient age was 70.5 years (range 46-85). The mean perceived/reported increase in survival with ADT was 5.0%, 8.5%, and 9.9% at 5, 10, and 15-year intervals. Hot flashes were the most reported side effect of ADT in all three cohorts (59%-81%). Other cited side effects included decreased libido, fatigue, and weight gain. 27.2% of patients in cohort 1 felt that their physician spent too little time discussing ADT and 54.5% felt that they were only able to ask half or less of the questions they had about ADT. The vast majority of patients believed that receiving written information on ADT would be helpful both before and after the initiation of ADT (97.6% and 96.4%, respectively, in all patients). Conclusions: Hot flashes are the most common side effect for patients on ADT. Information needs of patients on ADT can be better addressed by allocating more time at the initial patient visit, discussing side effect profiles during follow-up visits, as well as making written information available in the clinic at initial and subsequent visits. No significant financial relationships to disclose.
Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages
Authors: Charlotte Pawlyn, Annamaria Brioli, Walter Gregory, Samantha Hinsley, Jindriska Lindsay, Gordon Cook, Donald Milligan, Claire Chapman, Roger G Owen, Mark T Drayson, Nigel Russell, Graham H Jackson, Faith E Davies, Gareth J Morgan
Journal: Blood (2013)
Multiplexed quantitation of growth factor receptors and pathway activation in FFPE tumor tissue from the COIN trial.
Authors: R. Adams, T. A. Hembrough, S. Thyparambil, D. Krizman, M. Darfler, B. Jasani, T. Maughan, R. S. Kaplan, J. Burrows
Journal: Journal of Clinical Oncology (2011)

e14117 Background: The epidermal growth factor receptor (EGFR) is the target of antibody therapeutics, with cetuximab approved for use in metastatic colorectal carcinoma (mCRC) among other indications. While KRAS mutation is a negative predictor of cetuximab response, patients with wtKRAS may show low response rates through a number of resistance mechanisms. Co-expression of receptor tyrosine kinases, such as IGF1R or cMet, can confer resistance by providing alternative ways to activate tumor growth pathways. Additionally, current diagnostic assays cannot quantitate receptor or pathway activation in tissue. Characterization of these various resistance mechanisms are critical to maximizing response rates to EGFR targeted therapies. Methods: In order to address these issues, we used mass spectrometry to develop a multiplexed SRM (selective reaction monitoring) assay to measure levels of multiple protein targets on FFPE tumor tissue. These assays are based on the Liquid Tissue-SRM technology platform. This approach enables relative and absolute quantification of proteins and their phosphorylation status directly in formalin fixed paraffin embedded (FFPE) tissue. Results: Using these multiplexed SRM assays we measured expression of EGFR, IGF1R and cMet, in 32 colorectal carcinoma samples from the COIN trial. EGFR expression in these tumors, ranged from less than 100amol to 1,200amol/ug of tumor protein. Of particular interest was the expression of potential resistance markers. Of 32 tumors characterized, 4 tumors showed no expression of EGFR, 19 expressed either cMet or IGF1R, and 4 tumors expressed both receptors. We are continuing analysis on a second cohort of 40 tumors, and will reconcile these results with clinical outcome data. Since active EGFR is necessary for the response to these therapies, we have initiated a phospho-SRM mass spectrometry strategy to quantitate activation of EGFR, other candidate resistance receptors and signaling pathway components in these same COIN trial tissues. This data will be presented. Conclusions: The ability to absolutely quantify and compare critical biomarkers in the same tumor cells represents a profound step forward for the diagnostic space.
Angiogenic Molecules and Inflammatory Cytokines in Patients with Thalassemia Major and Double Heterozygous HbS/Beta-Thalassemia; the impact of Deferasirox.
Authors: Ersi Voskaridou, Dimitrios Christoulas, Athanasios Papatheodorou, Eleni Plata, Charoula Xirakia, Panayiotis Tsaftaridis, Georgios Boutsikas, Evangelos Terpos
Journal: Blood (2009)
Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens
Authors: Thuy Doan, Michael R. Wilson, Emily D. Crawford, Eric D. Chow, Lillian M. Khan, Kristeene A. Knopp, Brian D. O’Donovan, Dongxiang Xia, Jill K. Hacker, Jay M. Stewart, John A. Gonzales, Nisha R. Acharya, Joseph L. DeRisi
Journal: Genome Medicine (2016)

Ocular infections remain a major cause of blindness and morbidity worldwide. While prognosis is dependent on the timing and accuracy of diagnosis, the etiology remains elusive in ~50 % of presumed infectious uveitis cases. The objective of this study is to determine if unbiased metagenomic deep sequencing (MDS) can accurately detect pathogens in intraocular fluid samples of patients with uveitis. This is a proof-of-concept study, in which intraocular fluid samples were obtained from five subjects with known diagnoses, and one subject with bilateral chronic uveitis without a known etiology. Samples were subjected to MDS, and results were compared with those from conventional diagnostic tests. Pathogens were identified using a rapid computational pipeline to analyze the non-host sequences obtained from MDS. Unbiased MDS of intraocular fluid produced results concordant with known diagnoses in subjects with (n = 4) and without (n = 1) uveitis. Samples positive for Cryptococcus neoformans, Toxoplasma gondii, and herpes simplex virus 1 as tested by a Clinical Laboratory Improvement Amendments-certified laboratory were correctly identified with MDS. Rubella virus was identified in one case of chronic bilateral idiopathic uveitis. The subject's strain was most closely related to a German rubella virus strain isolated in 1992, one year before he developed a fever and rash while living in Germany. The pattern and the number of viral identified mutations present in the patient's strain were consistent with long-term viral replication in the eye. MDS can identify fungi, parasites, and DNA and RNA viruses in minute volumes of intraocular fluid samples. The identification of chronic intraocular rubella virus infection highlights the eye's role as a long-term pathogen reservoir, which has implications for virus eradication and emerging global epidemics.
Vitamin D deficiency in Australian early-stage breast cancer patients starting aromatase inhibitors.
Authors: M. Harris, A. Vincent
Journal: Journal of Clinical Oncology (2010)

e19574 Background: Vitamin D deficiency is common, reported in 30-40% of community living Australian women. Vitamin D deficiency can cause reduced bone mineral density (BMD), bone pain and muscle weakness. Aromatase inhibitors (AIs) can also cause reduced BMD and musculoskeletal pain. We sought to determine the frequency of vitamin D deficiency in Australian early stage breast cancer patients commencing aromatase inhibitors. Methods: 50 post menopausal women with stage 1-3 breast cancer attending our Breast Unit between 5/08-9/09 were randomly selected to have their serum 25 hydroxy-vitamin D (25OHD) levels (n = 50) and dual X Ray bone densitometry ( n = 35) independently assessed on commencement of adjuvant AI therapy. Results: The median age of the women was 64 years (range 44-91),48/50 were Caucasian and all lived in the community. Five women were taking vitamin D supplements. Normal 25OHD levels (75-250 nmol/L) were only detected in 8/50 women. The majority of women (32/50) had 25OHD deficiency (<50nmol/L) with 25OHD insufficiency (50-75nmol/L) detected in 10/ 50 women. One half off those with 25OHD deficiency had levels less than 30nmol/L. Only one women taking vitamin D supplements had normal 25OHD levels. BMD data was available on 22/32 women with vitamin D deficiency; revealing 9 women with osteopenia (T score−1.0 to −2.5) and 4 women with osteoporosis (T score <−2.5). Osteopenia was also detected in 6 women with 25OHD insufficiency and in 1 patient with a normal Vitamin D level. Conclusions: Vitamin D deficiency/insufficiency is common in women with breast cancer commencing AI therapy and is associated with reduced BMD. Vitamin D deficiency/insufficiency appears to occur more frequently in women with breast cancer compared with the general community. Serum 25OHD levels should be routinely assessed on commencement of AI therapy and any insufficiency/deficiency corrected to minimise bone loss/musculoskeletal complications. No significant financial relationships to disclose.
P1301 : A novel role for krüppel-like-factor 6 in hepatic regeneration and acute liver failure
Authors: S. Sydor, J. Best, P. Manka, F.J. Cubero, M. Schlattjan, T. Schreiter, D. Vetter, A. Paul, S.L Friedman, G. Gerken, A. Canbay, L.P. Bechmann
Journal: Journal of Hepatology (2015)
Mortality From Pneumonia and Hip Fractures in Patients With Advanced Dementia
Authors: Ken-ichiro Inoue, Manabu Sawada, Sumire Kawai, Risa Nakahara, Hajime Sano
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma
Authors: Ryusuke Nakamoto, Yuji Nakamoto, Takayoshi Ishimori, Kaori Togashi
Journal: Clinical Nuclear Medicine (2016)

This retrospective study compared the diagnostic performances of quantitative versus visual analyses of I-MIBG scintigraphy in patients with suspected pheochromocytoma and paraganglioma (PPGL).SPECT images were obtained 6 and/or 24 h after MIBG injection from 68 patients with clinically suspected PPGL, with attenuation correction by low-dose unenhanced CT. Planar images were also obtained at each time point. SUVs of retroperitoneal tumors, including PPGLs, and physiological uptake by normal organs were measured using the SPECT images. The diagnostic performance of the quantitative assessment in differentiating PPGLs from other lesions or normal adrenal glands was assessed using receiver operating characteristic analysis. The planar scans and 6-h and 24-h SPECT/CT images were also assessed visually.PPGLs showed a significantly higher SUVmax (mean ± SD = 9.97 ± 3.86) than other retroperitoneal lesions (3.85 ± 1.51) or normal adrenal glands (3.91 ± 1.20). At an optimal cut-off of 6.57, the sensitivity, specificity, and accuracy of the quantitative assessment for 6-h SPECT/CT in differentiating PPGLs was 78.6%, 96.3%, and 92.6%, respectively; the area under the curve was 0.878. The diagnostic performance did not significantly differ between the quantitative and visual analyses, but the specificity of the former tended to be higher at 6 h (96.3% vs. 90.7%) and at 24 h (91.2% vs. 82.4%).The specificity, but not the sensitivity, of the quantitative approach was higher than that of visual assessment in differentiating PPGLs from other retroperitoneal pathologies and from physiological uptake in the normal adrenal gland.
Interference With TNFα Using Long-Term Etanercept In S+SAntilles Sickle Transgenic Mice Ameliorates Abnormal Endothelial Activation, Vasoocclusion, and Pulmonary Hypertension Including Its Pulmonary Arterial Wall Remodeling
Authors: Anna Solovey, Arif Somani, Chunsheng Chen, James Kiley, Paul Marker, Fuad Abdulla, M Gerard O'Sullivan, Robert J Kelm, John D Belcher, Gregory M Vercellotti, Robert P Hebbel
Journal: Blood (2013)
Remaining Questions Concerning Wearable Devices
Authors: Nitika Pant Pai, Diandra Budd
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
NHS misses key performance targets again in June
Authors: Matthew Limb
Journal: BMJ (2016)

NHS trusts in England continued to miss key performance targets as pressure mounted on services, new statistics show.

Figures for June 2016 show that the NHS failed to meet major standards on access to urgent, emergency, and planned care.1 In June 90.5% of patients coming to hospital emergency departments were seen within four hours of arrival, a slight increase from 90.2% in May but below the 95% standard set by the government. Figures for nine ambulance trusts showed that just over 69% of ambulances reached the most serious callouts within eight minutes. It is the 13th month in a row …
Le réseau de surveillance international Enter-net - objectifs et organisation
Authors: I. S.T. Fisher
Journal: Eurosurveillance (1999)

Enter-net est un reseau de surveillance international des infections gastro-intestinales humaines charge de controler les salmonelles et Escherichia coli O157 producteurs de verotoxine (VTEC), y compris leur resistance antimicrobienne. A sa creation, le reseau comprenait les 15 pays de l’Union Europeenne (UE), ainsi que la Suisse et la Norvege (Carte). Finance par la Commission Europeenne (CE), Enter-Net est le prolongement du reseau Salm-Net (1994-97) cree pour harmoniser les procedures de lysotypage des salmonelles et mettre en place une base de donnees internationale, mise a jour regulierement, sur les salmonelles. La detection et l’investigation d’epidemies realisees dans le cadre de Salm-Net ont montre qu’un echange rapide d’informations entre les experts des differents pays de l’UE permettait de mener des actions de sante publique efficaces en Europe et au-dela. Enter-net poursuit ces activites et les etend a la prevention des infections par E.coli O157.
Trends in quality of screening colonoscopy in Austria
Authors: Elisabeth Waldmann, Irina Gessl, Daniela Sallinger, Philip Jeschek, Martha Britto-Arias, Georg Heinze, Elisabeth Fasching, Werner Weiss, Michael Gschwantler, Michael Trauner, Monika Ferlitsch
Journal: Endoscopy (2016)

<b>Background and study aim:</b> Screening colonoscopy only effectively prevents colorectal cancer if performed with high quality. The aim of this study was to analyze the detection rates of premalignant colorectal lesions in screening colonoscopies performed within a nationwide quality control program for screening colonoscopy in Austria. <b>Methods:</b> Data from electronic records of the screening program from its implementation in 2007 until December 2014 were analyzed in order to calculate detection rates for adenomas, advanced adenomas, polyps, and proximal lesions, and rates of cecal intubation, sedation, complications, and adequate bowel preparation. Results were evaluated to identify trends and changes in quality parameters over the 8-year study period. <b>Results:</b> During the study period, 301 endoscopists provided data from 159 246 screening colonoscopies. Mean age of screened individuals was 61.1 years, and 49.1 % were women. Significant increases over time were found for age- and sex-adjusted adenoma detection rates (ADRs), which increased from a mean of 22.2 % (SD 10.7 %) in 2007/2008 to 24.2 % (SD 11.6 %) in 2013/2014. On average, each endoscopist increased their individual ADR by + 1.5 percentage points per 2-year period (95 % confidence interval [CI] 0.9 – 2.2 percentage points; <i>P</i> < 0.01). Similarly, detection rates for proximal lesions rose from 15.8 % (SD 9.8 %) to 21.7 % (SD 13.3 % + 2.5 percentage points per 2-year period, 95 %CI 1.9 – 3.1 percentage points; <i>P</i> < 0.01). ADR in men increased from 27.6 % in 2007/2008 (SD 11.1 %) to 29.2 % in 2013/2014 (SD 12.7 %; <i>P</i> < 0.01); ADR in women increased from 14.2 % (SD 7.1 %) in 2007/2008 to 19.0 % (SD 10.5 %) in 2013/2014 (<i>P</i> < 0.01). Advanced adenoma detection rates decreased during the study period, from 11.4 % (SD 9.0 %) in 2007/2008 to 7.6 % (SD 5.4 %) in 2013/2014 (<i>P</i> = 0.06) in men, and from 5.5 % (SD 5.3 %) in 2007/2008 to 4.0 % (SD 4.1 %) in 2013/2014 in women (<i>P</i> = 0.21). <b>Conclusions:</b> This study showed an improvement in the quality of screening colonoscopies performed within a quality assurance program in Austria between 2007 and 2014. Although, overall ADR increased significantly during the study period, there was a decrease in the rate of advanced adenoma detection.
Genital Herpes
Authors: John W. Gnann, Richard J. Whitley
Journal: New England Journal of Medicine (2016)

Herpes simplex virus type 1 and type 2 cause genital herpes. Antiviral therapy is used for symptomatic outbreaks, and as daily suppressive therapy, it reduces recurrences of symptoms, asymptomatic viral shedding, and the risk of HSV-2 transmission.
Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors.
Authors: W. Kromdijk, A. D. Huitema, M. E. Kemper, J. H. Schellens, D. Richel, H. Klumpen
Journal: Journal of Clinical Oncology (2010)

2572 Background: Temsirolimus (CCI-779, TEM) is a selective inhibitor of mTOR with anticancer activity in a limited number of cancer types. A potential mechanism of drug resistance of TEM is feedback activation of the PI3k signaling pathway. Dual inhibition of PI3 kinase and mTOR may overcome this resistance. Nelfinavir (NFV), a human immunodeficiency protease inhibitor and a strong CYP3A4 inhibitor, has PI3kinase-inhibiting activity. In this phase I dose-escalation study TEM and NFV were combined (start dose of weekly 10 mg IV TEM infusion and daily 1,500 mg oral NFV in a 3-week cycle). Methods: Standard dose escalation was used in cohorts of 3-6 patients (pts). PK profiles of TEM, its active metabolite sirolimus (SIR), and NFV were obtained in each pt after the first administration and after combination of TEM and NFV (D1, D4, and D11of Cycle 1). Peripheral blood mononuclear cells and, where possible, tumor material of pts were obtained to determine the PD effects. Results: Pretreated pts received NFV at dose level 1 (1,500 mg, 7 pts) and dosel evel 0 (1,000 mg, 3 pts) in combination with 10mg TEM. Pts (6 females, 4 males, median age: 49 years [24-66], WHO 0-2, main tumor types: pancreas, glioblastoma, sarcoma, and galbladder) received up to 6 cycles. The most common reason for treatment discontinuation was disease progression. DLT was seen in 2 pts at dose level 1 (1,500 mg NFV and 10 mg TEM): grade 3 mucositis and nausea. Ulcerative mucositis was the most common toxicity (all grades) (7/10pts), then nausea (5/10 pts) and diarrhea (5/10pts). Neither CRs nor PRs were observed. TEM plasma exposure alone and in combination with NFV did not change (mean AUC0-24 1,435 vs. 1,250 nghr/mL, respectively), while SIR plasma exposure increased when TEM was combined with NFV (mean AUC0-24 678 vs. 1,050 respectively, p<0.05). NFV showed a high interpatient variability alone as well as in combination with TEM (CV= 55 and 71%, respectively). Pharmacodynamic investigations are ongoing. Conclusions: Nelfinavir 1,000 mg/day and temsirolimus 10 mg/wk can be safely combined. DLT was mucositis and nausea. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Wyeth